Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-20
2005-12-20
Huang, Evelyn Mei (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S210210, C514S243000, C514S247000, C514S264100, C546S122000, C544S184000, C544S236000, C544S279000
Reexamination Certificate
active
06977261
ABSTRACT:
This invention provides compounds defined by Formula Ior a pharmaceutically acceptable salt thereof,wherein R1, Q, Y, R2, R3, R4, R5, and n are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.
REFERENCES:
patent: 5367078 (1994-11-01), Ohno et al.
patent: 6008243 (1999-12-01), Bender et al.
patent: 6245778 (2001-06-01), Hadley et al.
patent: 6656932 (2003-12-01), Picard et al.
patent: 2002/0151555 (2002-10-01), Barvian et al.
patent: 2002/0151558 (2002-10-01), Andrianjara et al.
patent: 2002/0156061 (2002-10-01), Barvian et al.
patent: 2002/0156069 (2002-10-01), Picard et al.
patent: 2002/0161000 (2002-10-01), Barvian et al.
patent: 2002/0193377 (2002-12-01), Andrianjara et al.
patent: 2003/0004172 (2003-01-01), Harter et al.
patent: 2003/0078276 (2003-04-01), Andrianjara et al.
patent: 2003/0087924 (2003-05-01), Sorenson
patent: 2003/0130278 (2003-07-01), Gaudilliere et al.
patent: 2003/0144274 (2003-07-01), Bunker et al.
patent: 2003/0216402 (2003-11-01), Gaudilliere et al.
patent: 2003/0220355 (2003-11-01), Gaudilliere et al.
patent: 2004/0006077 (2004-01-01), Gaudilliere et al.
patent: 0935963 (1999-08-01), None
patent: 1138680 (2001-10-01), None
patent: WO 00/09485 (2000-02-01), None
patent: WO 01/12611 (2001-02-01), None
patent: WO 01/63244 (2001-08-01), None
patent: WO 02/34726 (2002-05-01), None
patent: WO 02/34753 (2002-05-01), None
patent: WO 02/064080 (2002-08-01), None
patent: WO 02/064080 (2002-08-01), None
patent: WO 02/064547 (2002-08-01), None
patent: WO 02/064547 (2002-08-01), None
patent: WO 02/064568 (2002-08-01), None
patent: WO 02/064571 (2002-08-01), None
patent: WO 02/064572 (2002-08-01), None
patent: WO 02/064578 (2002-08-01), None
patent: WO 02/064595 (2002-08-01), None
patent: WO 02/064598 (2002-08-01), None
patent: WO 02/064599 (2002-08-01), None
patent: WO 03/032999 (2003-04-01), None
patent: WO 03/033478 (2003-04-01), None
patent: WO 03/076417 (2003-09-01), None
patent: WO 03/076417 (2003-09-01), None
patent: WO 04/000322 (2003-12-01), None
Morphy et al. Current Medicinal Chemistry, 1995, 2(3): 743-762.
From PCT/IB03/03485 International Search Report.
Office Action from 10/264,764, mailed Jun. 16, 2003.
Chen et al., “Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utiliziing NMR Spectroscopy and Computer-Aided Molecular Design”, JACS, 2000; 122: 9648-9654.
Lovejoy, et al., “Crystal structures of MMP-1 and -13 reveal the stuctural basis for selectivity of collagenase inhibitors”, Nature Structual Biol., 1999; 6; 217-221.
Moy, et al., “High-resolution Solution Structure of the Catalytic Fragment of Human Collagenase-3 (MMP-13) Complexed with a Hydroxamic Acid Inhibitor”, J. Mol. Biol., 2000; 302:671-689.
Mitchell, et al., “Cloning, Expression, and Type II Collagenolytic Activity of Matrix Metalloproteinase-13 from Human Osteoarthritic Cartilage”, J. Clin. Invest., 1996; 97(3):761-768.
Neuhold, et al., “Postnatal expression in hyaline cartilage of constituitively active human collagenase-3 (MMP-13) induces osteoarthritis in mice”, J. Clin. Invest., 2001; 107(1):35-44.
Dahlberg, et al., “Selective Enhancement of Collagenase-Mediated Cleavage of Resident Type II Collagen in Cultured Osteoarthritic Cartilage Arrest with a Synthetic Inhibitor That Spares Collagenase 1 (Matrix Metalloproteinase 1)” Arthrit. & Rheum., 2000; 43(3):673-682.
Billinghurst, et al., “Comparison of the Degradation of Type II Collagen and Proteoglycan in Nasal and Articular Cartilages Induced by Interleukin-1 and the Selective Inhibition of Type II Collagen Cleavage by Collagenase”, Arthrit. & Rheum., 2000; 43(3):664-672.
Billinghurst, et al., “Enhanced Cleavage of Type II Collagen by Collagenase in Osteoarthritic Articular Cartilage”, J. Clin. Invest., 1997; 99(7):1534-1545.
Hirota, et al., “Novel Synthesis of Pyrido[3,4-d]Pyrimidines, Pyridol[2,3-d]-Pyrimidines, And Quinazolines Via Palladium-Catalyzed Oxidative Coupling”, Heterocycles, 1994: 37(1):563-570.
Wernicke, et al., “Cloning of Collagenase 3 from the Synovial Membrane and Its Expression in Rheumatiod Arthritis and Osteoarthritis”, J. Rheum., 1996; 23:590-595
Reboul, et al., “The New Collagenase, Collagenase-3, Is Expressed and Synthesized by Human Chondrocytes but not by Synoviocytes”, J. Clin. Invest., 1996; 97:2011-2019.
Freemont, et al., “In situ zymographic localisation of type II collagen degrading activity in osteoarthritic human articular cartilage”, Ann. Rheum, Dis., 1999; 58:357-365.
U.S. Appl. No. 10/071,032, filed Feb. 8, 2002, Dyer et al.
U.S. Appl. No. 10/634,531, filed Aug. 5, 2003, Johnson.
U.S. Appl. No. 10/634,709, filed Aug. 5, 2003, Bunker et al.
U.S. Appl. No. 10/634,162, filed Aug. 5, 2003, Wilson.
U.S. Appl. No. 10/634,473, filed Aug. 5, 2003, Bunker et al.
U.S. Appl. No. 10/634,180, filed Aug. 5, 2003, Bunker et al.
U.S. Appl. No. 10/634,712, filed Aug. 5, 2003, Hicks et al.
U.S. Appl. No. 10/634,181, filed Aug. 5, 2003, Li.
U.S. Appl. No. 10/634,489, filed Aug. 5, 2003, Roark.
U.S. Appl. No. 10/634,420, filed Aug. 5, 2003, Roark.
U.S. Appl. No. 10/634,716, filed Aug. 5, 2003, Nahara et al.
U.S. Appl. No. 10/634,288, filed Aug. 5, 2003, O'Brien.
U.S. Appl. No. 10/634,717, filed Aug. 5, 2003, Nahra et al.
U.S. Appl. No. 10/634,177, filed Aug. 5, 2003, Wilson.
U.S. Appl. No. 10/634,290, filed Aug. 5, 2003, Wilson.
U.S. Appl. No. 10/634,182, filed Aug. 5, 2003, Li.
U.S. Appl. No. 10/634,419, filed Aug. 5, 2003, Hicks et al.
U.S. Appl. No. 10/634,713, filed Aug. 5, 2003, Picard.
U.S. Appl. No. 10/634,225, filed Aug. 5, 2003, Picard et al.
U.S. Appl. No. 10/634,718, filed Aug. 5, 2003, Ortwine.
U.S. Appl. No. 10/739,261, filed Dec. 18, 2003, Bunker.
Bunker Amy Mae
Picard Joseph Armand
Ashbrook Charles W.
Huang Evelyn Mei
Pfizer Inc.
Purchase, Jr. Claude F.
Warner-Lambert Company LLC
LandOfFree
Azaisoquinoline derivatives as matrix metalloproteinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Azaisoquinoline derivatives as matrix metalloproteinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azaisoquinoline derivatives as matrix metalloproteinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3515872